Keynote (green)Duocarmycin-based antibody–drug conjugates as an emerging biotherapeutic entity for targeted cancer therapy: Pharmaceutical strategy and clinical progress
Keywords
Abbreviations
Cited by (0)
Ming-Hai Wang MD, PhD holds an Amarillo Community Endowed Chair for Cancer Biology Research and is the Director of the Cancer Biology Research Center at the Jerry H. Hodge School of Pharmacy at Texas Tech University Health Sciences Center. Dr Wang also is a tenured Professor in the Department of Pharmaceutical Sciences at Texas Tech University. For the past 30 years, Dr Wang has focused his research on the pathogenesis of receptor tyrosine kinases such as RON and MET in colon, breast, and pancreatic cancers, with emphasis on the clinical development of targeted biotherapeutics such as antibody–drug conjugates. Dr Wang has published extensively on these topics and has presented his research findings at various conferences across the world.
- 1
Author contributions: HPY and HZ contributed equally to this work.